Officially Listed in Chile's National Health Insurance in April This Year

Celltrion announced on December 2 that it has launched 'Remsima SC', the world's only subcutaneous formulation of infliximab, in Chile, marking its first entry into the public market in Latin America.

Remsima SC. Celltrion

Remsima SC. Celltrion

View original image

After obtaining product approval for Remsima SC from the Chilean Public Health Institute (ISP) in April 2023, Celltrion has been in ongoing discussions with the government to secure inclusion in the national health insurance system. Celltrion's Chilean subsidiary submitted a wide range of materials, including clinical data and published papers, to relevant institutions following the approval. As a result, Remsima SC was officially listed in Chile's national health insurance in April this year. About seven months later, the first sales of Remsima SC were made in Chile's public market.


In Latin America, the pharmaceutical supply channels are divided between the public and private markets in an 8:2 ratio, making the public market the key channel for product sales.


The rapid launch was largely driven by strong requests from major local stakeholder groups for the introduction of Remsima SC. The Chilean Inflammatory Bowel Disease (IBD) Society officially submitted a letter from its president to the review agency, requesting the inclusion of Remsima SC in the national health insurance. Additionally, local patient advocacy groups raised their voices to the government, emphasizing the need for Remsima SC to be listed, and both healthcare professionals and patients directly involved in prescriptions actively requested its inclusion, leading to swift results.


The high evaluation of Remsima SC's competitiveness by Chilean regulatory authorities also played a significant role. During the 'New Drug Listing Review Committee' meeting for national health insurance inclusion, more than 10 medicines were considered for final review, but Remsima SC was the only one successfully listed. This is interpreted as recognition that the product's safety, efficacy, and cost-effectiveness have already been validated in major global markets such as Europe and North America.


With the initial supply now completed, patient preference is shifting from the IV formulation to the SC formulation, which is expected to drive significant growth going forward. In addition, since existing products such as Remsima IV, Truxima (ingredient: rituximab), Herzuma (ingredient: trastuzumab), and Yuflyma (ingredient: adalimumab) are all supplied to Chile's public market, Celltrion plans to leverage marketing synergies among these products to secure early market leadership.



Kang Kyungdoo, Head of Celltrion's Latin America Division, stated, "With the new launch of Remsima SC, we expect that Chilean patients suffering from autoimmune diseases will have broader treatment options and experience improved quality of life. As local healthcare professionals and patient advocacy groups strongly advocated for the inclusion of Remsima SC during the national health insurance process, we were able to expedite our achievements. We plan to actively capitalize on the clearly identified market needs and preferences to pursue even more aggressive marketing activities."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing